KRAS and pancreatic ductal adenocarcinoma: KRAS oncogenic point mutations, which constitutively activate the RAS signaling pathway, affect the regulation of multiple cellular biological processes in pancreatic ductal adenocarcinoma, including cell proliferation, migration, metabolism and autophagy.